Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Chemours (CC) EBT (2016 - 2025)

Chemours (CC) has 12 years of EBT data on record, last reported at $387.0 million in Q4 2025.

  • For Q4 2025, EBT rose 38600.0% year-over-year to $387.0 million; the TTM value through Dec 2025 reached $140.0 million, up 29.63%, while the annual FY2025 figure was $176.0 million, 38.58% up from the prior year.
  • EBT reached $387.0 million in Q4 2025 per CC's latest filing, up from $38.0 million in the prior quarter.
  • Across five years, EBT topped out at $387.0 million in Q4 2025 and bottomed at -$433.0 million in Q2 2023.
  • Average EBT over 5 years is $25.0 million, with a median of $41.0 million recorded in 2021.
  • The widest YoY moves for EBT: up 38600.0% in 2025, down 494.2% in 2025.
  • A 5-year view of EBT shows it stood at -$330.0 million in 2021, then grew by 13.33% to -$286.0 million in 2022, then surged by 75.17% to -$71.0 million in 2023, then surged by 101.41% to $1.0 million in 2024, then skyrocketed by 38600.0% to $387.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were $387.0 million in Q4 2025, $38.0 million in Q3 2025, and -$272.0 million in Q2 2025.